Literature DB >> 21719602

Type I-IFNs control GVHD and GVL responses after transplantation.

Renee J Robb1, Ellen Kreijveld, Rachel D Kuns, Yana A Wilson, Stuart D Olver, Alistair L J Don, Neil C Raffelt, Nicole A De Weerd, Katie E Lineburg, Antiopi Varelias, Kate A Markey, Motoko Koyama, Andrew D Clouston, Paul J Hertzog, Kelli P A Macdonald, Geoffrey R Hill.   

Abstract

Although the effects of type II-IFN (IFN-γ) on GVHD and leukemia relapse are well studied, the effects of type I-interferon (type I-IFN, IFN-α/β) remain unclear. We investigated this using type I-IFN receptor-deficient mice and exogenous IFN-α administration in established models of GVHD and GVL. Type I-IFN signaling in host tissue prevented severe colon-targeted GVHD in CD4-dependent models of GVHD directed toward either major histocompatibility antigens or multiple minor histocompatibility antigens. This protection was the result of suppression of donor CD4(+) T-cell proliferation and differentiation. Studies in chimeric recipients demonstrated this was due to type I-IFN signaling in hematopoietic tissue. Consistent with this finding, administration of IFN-α during conditioning inhibited donor CD4(+) proliferation and differentiation. In contrast, CD8-dependent GVHD and GVL effects were enhanced when type I-IFN signaling was intact in the host or donor, respectively. This finding reflected the ability of type I-IFN to both sensitize host target tissue/leukemia to cell-mediated cytotoxicity and augment donor CTL function. These data confirm that type I-IFN plays an important role in defining the balance of GVHD and GVL responses and suggests that administration of the cytokine after BM transplantation could be studied prospectively in patients at high risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719602     DOI: 10.1182/blood-2010-12-325746

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

Authors:  Marcos de Lima; David L Porter; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Christoph Schmid
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

3.  Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Authors:  B Lamarthée; F Malard; C Gamonet; C Bossard; M Couturier; J-C Renauld; M Mohty; P Saas; B Gaugler
Journal:  Mucosal Immunol       Date:  2015-07-08       Impact factor: 7.313

4.  STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets.

Authors:  Cameron S Bader; Henry Barreras; Casey O Lightbourn; Sabrina N Copsel; Dietlinde Wolf; Jingjing Meng; Jeonghyun Ahn; Krishna V Komanduri; Bruce R Blazar; Lei Jin; Glen N Barber; Sabita Roy; Robert B Levy
Journal:  Sci Transl Med       Date:  2020-07-15       Impact factor: 17.956

5.  Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity.

Authors:  Ashraful Haque; Shannon E Best; Marcela Montes de Oca; Kylie R James; Anne Ammerdorffer; Chelsea L Edwards; Fabian de Labastida Rivera; Fiona H Amante; Patrick T Bunn; Meru Sheel; Ismail Sebina; Motoko Koyama; Antiopi Varelias; Paul J Hertzog; Ulrich Kalinke; Sin Yee Gun; Laurent Rénia; Christiane Ruedl; Kelli P A MacDonald; Geoffrey R Hill; Christian R Engwerda
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

6.  Pegylated interferon-2α invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation.

Authors:  Andrea S Henden; Antiopi Varelias; Justine Leach; Elise Sturgeon; Judy Avery; Jessica Kelly; Stuart Olver; Luke Samson; Gunter Hartel; Simon Durrant; Jason Butler; Anthony J Morton; Ashish Misra; Siok-Keen Tey; Elango Subramoniapillai; Cameron Curley; Glen Kennedy; Geoffrey R Hill
Journal:  Blood Adv       Date:  2019-10-22

7.  Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis.

Authors:  Kymberly M Gowdy; Julia L Nugent; Tereza Martinu; Erin Potts; Laurie D Snyder; W Michael Foster; Scott M Palmer
Journal:  Am J Respir Cell Mol Biol       Date:  2011-09-29       Impact factor: 6.914

8.  Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin.

Authors:  J S Lehman; S Dasari; S S Damodaran; R A El-Azhary; L E Gibson; S K Hashmi; W J Hogan; S J Kenderian; M S Patnaik; M R Litzow; H M Lazarus; A Meves
Journal:  Clin Exp Dermatol       Date:  2018-10-02       Impact factor: 3.470

9.  Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction.

Authors:  Yuanyuan Tian; Lijun Meng; Ying Wang; Bohan Li; Hongshuang Yu; Yan Zhou; Tien Bui; Ciril Abraham; Alicia Li; Yongping Zhang; Jian Wang; Chenchen Zhao; Shin Mineishi; Stefania Gallucci; David Porter; Elizabeth Hexner; Hong Zheng; Yanyun Zhang; Shaoyan Hu; Yi Zhang
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

10.  PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.

Authors:  Katiri J Snyder; Nina C Zitzer; Yandi Gao; Hannah K Choe; Natalie E Sell; Lotus Neidemire-Colley; Anora Ignaci; Charuta Kale; Raymond D Devine; Maria G Abad; Maciej Pietrzak; Min Wang; Hong Lin; Yang W Zhang; Gregory K Behbehani; Jane E Jackman; Ramiro Garzon; Kris Vaddi; Robert A Baiocchi; Parvathi Ranganathan
Journal:  JCI Insight       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.